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SIROLIMUS AND TACROLIMUS WITHOUT METHOTREXATE TO PRE- 
VENT GRAFT-VS-HOST DISEASE AFTER MATCHED, RELATED STEM 
CELL TRANSPLANTATION 
Cz~tler, C.; Ho, V.; Alyea, E.; Lee, S.J.; Soiffer, R.J.; Ant&, J.H. Med- 
ical O?zcology, Dana-Farber Cancer Institute, Boston, ]FLq. 
Sirolinms (Rapamune) is an immunosuppressive macrocyclic lac- 
tone similar in structure to tacrolimus and cyclosporine with a dis- 
tinct mechanism of action and toxicity profile. The drug has been 
used extensively in solid organ transplantation a d more recently, 
in stem cell transplantation. Methotrexate is a commonly used 
immunosuppressive agent that may paradoxically contribute to 
GVHD and transplantation-related toxicity indirectly through tis- 
sue damage. We tested the hypothesis that the synergistic combi- 
nation of sirolimus and tacrolimus would 1) result in effective 
GVHD prevention, 2) lead to rapid hematopoietic engraftment 
and 3) minimize transplant-related oxicity due to the omission of 
methotrexate. METHODS: To date, 9 patients have been treated 
with sirolimus (12 mg oral loading dose, 4 mg oral daily dose to 
maintain a level of 3-12 ng/ml) and tacrolimus (5-10 ng/ml serum 
level). All patients received cyclophosphamide (1800 mg/m2/day x 
2) followed by TBI (14 Cry in 7 fractions). Peripheral blood stem 
ceils from matched, related donors were infused on Day 0. Fil- 
grastim (5pg/kg) was administered from Day +12 until engraft- 
ment. RESULTS: The median patient age was 42 years (19-54) 
and 6/9 patients were male. Diagnoses included AML (6), NHL 
(2) and MDS (1). 6 patients had advanced isease. Oral sirolimus 
was well tolerated and therapeutic serum levels were attainable in 
all patients. All patients engrafted neutrophils at a median of 13 
days (range 12-I5) and platelets (> 20,000/gl) at a median of 13 
days (range 10-18). Grade 0-I acute GVHD occurred in 7/9 
patients. Grades II, III, and IV acute GVHD occurred in 2, 0 and 
0 patients respectively (total Grade II-IV GVHD 22%). The 
median time to first discharge was 20 days from transplantation 
(range 16-43). There was one case of non-fatal, severe VOD in a 
patient who had previously received Mylotarg. All patients remain 
alive at a median of 67 days, with one relapse in a patient with 
Burkitt's lymphoma. CONCLUSIONS:  The substitution of 
sirolimus for methotrexate is well tolerated and is associated with 
low regimen-related toxicity. There appears to be a reduction in 
the rate of acute GVHD using this synergistic ombination as 
well. This novel regimen is worthy of further study in allogeneic 
transplantation. We anticipate updated ata for presentation. 
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ACUTE RENAL FAILURE FOLLOWING NON-MYELOABLATIVE 
HEMATOPOIETIC STEM CELL TRANSPLANTATION - A MULTICEN- 
TER STUDY 
Parik,5, C.R.; McSweeney, P.; Schrier, R.W. U, iversi O, of Color,ado 
Health Scie,ces CeTzter, i)enve'r, CO. 
We have demonstrated that acute renal failure (ARF) is a con> 
mon life threatening complication following autologous and mye- 
loablative allogeneic hematopoietic stem cell transplantation 
(HSCT). The incidence of severe ARF, defined as doubling of 
serum creatinine, is 69% with myeloablative allogeneic HSCT. In 
this study 33% of the patients required dialysis and ARF occurred 
in the first 3 weeks after allogeneic HSCT. Non-myeloablative 
HSCT is a modification of conventional logeneic HSCT that is 
becoming a popular method ue to its safety and efficacy. It would 
be expected that severe ARF would be less with non-myeloablative 
HSCT, as the milder preconditioning re imen will cause less 
infections and less hypotension. The purpose of our study was to 
determine the course and severity of ARF associated with this pro- 
cedure. We analyzed the data collected on 286 patients who 
received non-myeloablative HSCT at 4 major university institu- 
tions (Fred Hutchinson Cancer Research Center, University of 
Colorado, Stanford University and City of Hope University). M1 
the patients who received non-myeloablative HSCT from 1998- 
2001 for hematological malignancy were included in the study. 
The patients were treated with multi-institutional shared proto- 
cols and thus preconditioning regimen and the post transplant 
imnmnosuppression were uniform. ARF was classified as mild 
(>25% increase in serum creatinine), severe (at least doubling of 
serum creatinine) and severe with dialysis. It was observed that the 
incidence of ARF is delayed and can be prolonged until 3 months 
after the non-myeloablative HSCT. The following table compares 
the risk of ARF from the non-myeloablative HSCT with the mye- 
loablative HSCT from our center. In summary, some degree of
ARf occured in 90% of the patients after non-myeloablative 
HSCT. The overall cumulative risk of developing severe ARF up 
to 3 months is 42 % with non-myeloablative patients. The require- 
ment of dialysis is ignificantly less in non-myelaoablative HSCT 
as compared to myeloabalative allogeneic HSCT (5% vs. 33%, 
P<0.01). In conclusion, although the patients receivcing the non- 
mycloablative transplant are older, the risk of developing renal 
failure and dialysis is ignificantly lower as compared to myeloab- 
lative HSCT. 
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LONG TERN COMPARISON OF RELAPSE AND OVERALL SURVIVAL 
IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AND 
ACUTE LYMPHOCYTIC LEUKEMIA (ALL) TREATED WITH UNRELAT- 
ED OR RELATED DONOR ALLOGENEIC MARROW/STEM CELL 
TRANSPLANTATION 
Al-Szdehz,1, S.Ad; Abel/a, Ed; /L~w~es, R.D.q Kara,es, C.:; Dmlsey, 
R.D. s 1. Hem./Olzc Division, Kmw~a,os Cmlcer i?zstitztte, DetJvit, MI; 
2. Nntio?lal Mmn'ow Donor Program, Mimzeapolis, MN. 
We have previously demonstrated no difference in surviwd for 
AML transplanted with either related (RD) or unrelated onors 
(URD) (:ASH 2001, abstract i719). This report extends our cxpe- 
rience comparing RD&URD transplants in patients with 
CML&ALL. Between August 1987 and June 2002, 120 patients 
with ALL and 213 patients with CML received alIogeneic trans- 
plants. 197 were males, and 136 were females with a mean age of 
32 years. 40 patients with ALL and 72 with CML received unre- 
lated donor marrow/stem cells, while the remaining patients 
received transplants ftom related onors. Pre-transplant ALL dis- 
ease status included CR1 in 29, >CR2 in 66, no remission in 22, 
and was unknown in 3 patients. Pre-transplant CML disease status 
included first chronic phase in 164, 2nd in 9, accelerated phase in 
25, blast crisis in 9, and unknown in 6 patients. Multiple condi 
tioning reghnens including busulphan (Bu) and cyclophosphamide 
(Cy), Cy / TBI, etoposide/TBI were used. GvHD prophyla~s was 
either cyclosporin or taerolimus with methotrexate or methyl- 
prednisolone. Overall, 154 (46%) are currently alive with 58 
(52%) deaths in the URD group and I21(55%) in the RD group 
and the longest survivor now at 11.4 years. The Kaplan-Meier dis- 
tribution of survival between URD & RD groups was not differ- 
ent by disease type (P = 0.57 for patients with ALL, P = 0.71 for 
patients with CML by the log rank test). This was true independ 
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ent of pretransplant disease status. The overali survival was better 
in CML patients transplanted in chronic phase (45-55%) or ALL 
patients transplanted in CR1 (33%7 whether from RD or URD (P 
< 0.057. There was no statistically significant difference in the 
relapse rate between RD & URD transplants for both ALL & 
CML patients with relapse mortality being 30% vs. 20% (p - 0.4) 
for ALL and 8% vs. 4% for CML (p=0.08). Acute GvHD of grade 
III or IV severity was observed in i5 % of the RD patients a  
compared to 27% of the URD patients. In conclusion, allogeneic 
transplantation from an URD at our institution appears to have 
equivalent outcome to transplant from RD for patients with CML 
or ALL. Transplantation f marrow from URD is reasonable and 
effective therapy for patients with CML or ALL who are candi- 
dates for allogeneic transplant, but has no RD. 
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EXTRACORPOREAL PHOTOPHORESIS AND PENTOSTATIN REDUCED 
INTENSITY PREPARATIVE REGIMEN: RESULTS IN PATIENTS WITH 
MYELODYSPLASTIC SYNDROME 
Chart, G.; Fos~, IV.; Klein, A.; SpJrlgzle, K.; 3/ii/ler, K. Tufts New Eng 
lm~d Medical Ce~teJ; Boston,, 3/IA. 
Substantial morbidity and mortality limits allogeneic stem cell 
transplantation for Myelodysplastie Syndrome (MDS) to 
younger patients with lower risk MDS. Sixteen patients (6M, 
10F), median age 53 years (range 32 to 70), with de novo (n=12) 
or therapy-related (n=4) NIDS underwent a reduced intensity 
preparative regimen of extracorporeal photophoresis for 2 days, 
pentostatin 8mg/m2 by continuous infusion over 48 hours, and 
600cGy TBI, followed by allogeneie bone marrow (n=15) or 
peripheral blood (n=l) stem cell infusion. GVHD prophylaxis 
consisted of cyelosporine A by continuous infusion and 
methotrexate. FAB subtypes included: RA (n=l), RARS (n=l), 
RAEB (n=10), RAEBT (n=3), and CMML (n=l). IPSS scores 
included: Low (n=l), Intermediate-1 (n=7), Intermediate-2 (n=5), 
and High (n=3). GVHD risk factors included: prior autoBMT 
(n=2), 5/6 HLA matched related donor (n=4), 6/6 matched unre- 
lated donor (n=4), age>50 years (n=10), and cytomegalovirus 
seropositivity (n=8). At a median follow-up of 10 months (range 
1-23), 14/16 patients developed full donor chimerism at engraft- 
ment with (n=l) or without (n=13) DLI. Nonrelapse mortality 
was 0% after 100 days and i9% after 1 year. Grade II and III-IV 
acute GVHD occurred in 7% and 14% of patients. Limited and 
extensive chronic GVHD developed in 25% and 42% of 
patients. One year relapsed free and overall survival was 60% 
and 63%. Patients died of disease progression failing engraft- 
ment (n-2), or acute (n=l) or chronic (n=3) GVHD. GVHD 
severity, nonrelapse mortality, relapse free and overall survival 
were similar among FAB or IPSS subtypes, but 6/6 matched 
related donors had less grade II-IV acute GVHD (p=0.0241) and 
better overall survival (p=0.0004). An extracorporeal pho- 
tophoresis and pentostatin reduced intensity preparative r gimen 
in high-risk MDS patients results in high rates of engraftment 
and survival with low rates of acute GVHD and disease relapse, 
but a high incidence of extensive chronic GVHD remains prob- 
lematic. 
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PERIPHERAL BLOOD STEM CELL VERSUS MARROW DONATION: 
EXPERIENCES OF 942 NMDP DONORS 
SzL, itze'r, G.EJ, Goycoolea, if.M J, Ha~7~aha, A.GJ; Dezz,, M J; Conifer, 
D.L.e; King, R.ff. 2 1. Medich~e, University of Pittsba~'gh 3/Iedical Cen- 
ter, Pittsbztrgh, PA; 2. National Mar'row Donor Program, MiTzneapo- 
lis, MN. 
The findings presented here represent the first comprehensive 
effort to examine psychosocial nd physical reactions to donation 
among Peripheral Blood Stem Cell (PBSC) versus marrow 
donors. Until recently, the PBSC donation procedure was used 
only infrequently among allogeneic donors, and then only in the 
context of second-time donation. In 1999, the NMDP imple- 
mented a PBSC donation protocol for first-time donors, and data 
collection for this project began. Longitudinal questionnaire data 
concerning donor demographic and psychosocial characteristics 
and donation-related decision processes and outcomes were gath- 
ered from 353 first-time PBSC donors (82% response) and a ran- 
domly selected comparison sample of 589 marrow donors (83% 
response) 2 weeks pre-donation, and 2 weeks post-donation. 
PBSC and marrow donors were virtually identical in terms of 
demographic characteristics and how quickly they made the dona- 
tion decision. Both groups felt equally prepared for donation, had 
low levels of ambivalence about donation, perceived the donation 
as moderately physically stressful, and felt good about having 
donated. However, PBSC donors were less likely than marrow 
donors to (a) have been encouraged (p<.001) or discouraged 
(p<.001) from donating by others, (b) report medical (p<.001) and 
family concerns (p<.01), (c) have donation related side effects and 
a longer post-donation recovery time (p<.001), and (d) perceive 
the donation as more painful than expected (p<.01). PBSC donors 
were more likely to have longer-term health concerns about dona- 
tion (p<.001). Conversely, although marrow donors had more 
physical difficulty with donation, they reported better mental 
health (p<.05), and higher self esteem (p<.01) post-donation. 
Overall, as compared to marrow donors, PBSC donors had less 
physical difficulty with donation, but more donation-related long- 
term health concerns and fewer psychosocial benefits. These find- 
ings provide strong evidence that PBSC is less physically demand- 
ing than marrow donation, and that the procedure is 
well-accepted by donors. 
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TEST DOSE PHARMACOKINETICS (PK) DIRECTED INTRAVENOUS 
BUSULFAN (IVBU) DOSING FOR HEMATOPOIETIC STEM CELL TRANS- 
PLANT (HSCT) PREPARATIVE REGIMENS 
Dickey, A.G.; Teresi, FV.M.; ~mghm~, I4~P.; Sal=man, D.E. UAB 
BMT Program, Bhwzing,~aJ:~, AL. 
Variation in the area under the concentration x time curve 
(AUC) for oral bu has been documented to result in a substantial 
risk of over or under treatment with excess risk of toxicity or 
relapse. The use of 1YBU reduces intra-patient variation in AUC 
by eliminating variation in absorption and clue to vomiting, 
although variation due to metabolism remains. In order to more 
accurately achieve a target AUC during the preparative r gimen, 
dose adjustment based on PK is necessary. This is typically done 
using PK determined on first dose administered resulting in 2 to 8 
doses of the typical 16 dose regimen being given before dose cor- 
rection. In this study patients were scheduled to receive 600mg of 
phenytoin the night before the test dose and then continued at 300 
mg twice daily until after the 16th dose. We performed PK studies 
following an IVBU test dose (15 mg/m2) to 8 adult patients at 
least 2 days prior to beginning a 16-dose IVBU containing BMT 
preparative regin, en. AUC was determined using an accurate 5- 
sample strategy analyzed using a single compartment, first order 
elimination model in the WinNonlin software as previously pub- 
lished by our group. We then chose the dose for administration as
first dose in the full 16-dose preparative regimen according to a 
linear assumption [First Dose = (Target AUC X Test Dose)/Test 
Dose AUC]. The Predicted Dose varied from the Target Dose as 
a result of rounding. Repeat PK was performed on the first dose to 
determine the utility of this approach (see table). In 5 patients the 
test dose PK predicted first dose AUC with less than 8% variation. 
The remaining 3underestimated first dose by an average of 18%. 
A phenytoin level obtained on one of those patients was 3.5 
whereas phenytoin levels on 3 of the 4 patients with low variation 
averaged >7%. These data suggest that better phenytoin loading 
or use of an alternate strategy for seizure prophylaxis will allow 
dosing precision with BU in HSCT preparative regimens. A great 
deal of research as been done defining maximum tolearted osing 
in preparative r gimens for allogeneic and autologous transplanta- 
tion; current research is heavily focused on defining minimum 
necessary dose for allogeneic transplantation. The dosing preci- 
sion permitted by PK directed therapy will permit research to 
define the optimum dose for each clinical setting. 
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